Recent News

Abemaciclib Plus Endocrine Therapy Approved by FDA for Early Breast Cancer

Breakthrough Therapy Designation Granted for T-DXd in HER2-Positive Breast Cancer

ESMO 2021: Interim Phase II Results With Dalpiciclib Plus Pyrotinib in HER2-Positive Breast Cancer

ESMO 2021: Subgroup Analysis of Asian Patients Treated With T-DM1 for Breast Cancer

ESMO 2021: Update From KEYNOTE-355 on Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

ESMO 2021: Neoadjuvant Giredestrant Versus Anastrozole in Postmenopausal Women With Early Breast Cancer

ESMO 2021: Long-Term Overall Survival With Letrozole Plus Ribociclib in Advanced Breast Cancer

ESMO 2021: DESTINY-Breast03 Trial of T-DXd Versus T-DM1 in HER2-Positive Breast Cancer

ESMO 2021: How Does 6 Months of Trastuzumab Measure Up to Longer Treatment in Early Breast Cancer?

ESMO 2021: COVID-19 Vaccination in Patients With Breast Cancer

Are Genetic Alterations Linked to Resistance to Antibody-Drug Conjugate in Triple-Negative Breast Cancer?

Long-Term Survival Update From Secondary Analysis of Stockholm Tamoxifen Trial

Can Statins Improve Outcomes in Patients With Triple-Negative Breast Cancer?

COVID-19 and Breast Cancer: Focus on Building Vaccine Acceptance

Manufacturer Withdraws Atezolizumab’s U.S. Indication in Triple-Negative Breast Cancer

FDA Issues Caution Statement on Use of Robotically Assisted Surgical Devices for Mastectomy

Postmenopausal Women With Breast Cancer: How Many Years of Adjuvant Endocrine Therapy Is Necessary?

Stromal Platelet-Derived Growth Factor Receptor-Beta Expression Biomarker for Early Breast Cancer

Preventing Trastuzumab-Induced Cardiotoxicity in Breast Cancer: Lisinopril or Carvedilol?

Patient Survey on Dosage Strategies and Tolerability of Breast Cancer Therapy

Estrogen Receptor Antagonist Under Study for Locally Advanced or Metastatic Breast Cancer

Managing Breast Cancer in Older Adults: An Updated International Policy Review

Can Serum Levels of Vitamin D at Diagnosis Predict Breast Cancer Prognosis?

Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer

FDA Brief: Trilaciclib Plus Chemotherapy Granted Fast Track Designation in Triple-Negative Breast Cancer

Early Results for Novel Combination in Metastatic Breast Cancer

Early-Phase Trials of Novel Antibody-Drug Conjugate in HER2-Overexpressed Solid Tumors

Pooled Analysis of HER2-Targeting Antibody-Drug Conjugate in Metastatic Breast Cancer

Fulvestrant With or Without Venetoclax in Locally Advanced or Metastatic Breast Cancer

Body Mass Index and Breast Cancer Outcomes by Racial Ancestry

Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer With Brain Metastases

ASCO 2021: Neoadjuvant Talazoparib Active in Germline BRCA1/2-Mutated HER2-Negative Breast Cancer

Patient With Breast Cancer Successfully Treated With Immunotherapy in Thailand Hospital

ASCO 2021: MONALEESA-3 Survival Update of Ribociclib/Fulvestrant for Advanced Breast Cancer

Updated ASCO Guideline for Managing Hereditary Breast Cancer

ASCO 2021: Long-Term Survival With Palbociclib Plus Fulvestrant in Advanced Breast Cancer

Treatment Implications of Breast Tumors’ Switch to HER2-Low Status in Recurrence

Implications of Symptom Burden Among Breast Cancer Survivors

ASCO 2021: Adjuvant Durvalumab Treatment for Triple-Negative Breast Cancer

ASCO 2021: Novel CDK4/6 Inhibitor Plus Fulvestrant Focus of Phase III Trial in Advanced Breast Cancer

ASCO 2021: Adjuvant Capecitabine Versus Platinum-Based Chemotherapy for Residual Triple-Negative Breast Cancer

ASCO 2021: COVID-19 Outcomes and Breast Cancer by Racial/Ethnic Group

Androgen Receptor–Targeting Agent Under Study in Metastatic Disease

ASCO 2021: Survival Outcomes With De-escalated Neoadjuvant Treatment of Early Breast Cancer

ASCO 2021: OlympiA Trial of Adjuvant Olaparib After Chemotherapy for Early-Stage Breast Cancer

ESMO Breast 2021: Atezolizumab Plus Carboplatin for Metastatic Invasive Lobular Cancer

ESMO Breast 2021: Distinct Gene Signatures Associated With Pathologic Complete Response

ESMO Breast 2021: Does Clinical Benefit From Endocrine Therapy Differ by Risk Group?

Adding Oral Alisertib to Weekly Paclitaxel for Metastatic Breast Cancer

ESMO Breast 2021: Clinical Role of RAD51 Testing in Triple-Negative Breast Cancer

ESMO Breast 2021: Safety Outcomes With Abemaciclib Plus Endocrine Therapy in Early Breast Cancer

Eribulin and Pembrolizumab Combination in Triple-Negative Breast Cancer

ASBrS 2021: Can Medicaid Expansion Improve Disparities in Breast Reconstruction?

APHINITY Trial Update: Adjuvant Pertuzumab-Based Therapy in Early HER2-Positive Breast Cancer

Treadmill and T Cells: Can Exercise Enhance Immune Responses in Breast Cancer?

Can Healthy Plant-Based Diets Decrease the Risk of Breast Cancer?

Predicting Response to Combination Therapies for Breast Cancer Brain Metastases

AACR 2021: Can Gut Microbiota Influence Treatment Response in Metastatic Breast Cancer

Distant Lymph Node Metastases From Breast Cancer: A Regional Disease?

AACR 2021: Using ctDNA Changes to Predict Response to Palbociclib-Based Therapy for Breast Cancer

AACR 2021: Talazoparib/Carboplatin Under Study in Triple-Negative Breast Cancer

Fixed-Dose Pertuzumab-Based Regimen Under Study in FeDeriCa Trial